Inactive Instrument
Biodexa Pharmaceuticals Plc Stock London S.E.
Stocks
BDRX
GB00BNGF1L75
Biotechnology & Medical Research
| Market Cap | 380K 506K 454K 419K 710K 48.02M 719K 5.02M 1.99M 25.17M 1.9M 1.86M 79.81M | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 380K 506K 454K 419K 710K 48.02M 719K 5.02M 1.99M 25.17M 1.9M 1.86M 79.81M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
0.04% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -11.76% |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 65 | 2020-03-30 |
Fiona Sharp
DFI | Director of Finance/CFO | 58 | 2026-01-04 |
Noreen Bhatti
CTO | Chief Tech/Sci/R&D Officer | - | 2024-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Sijmen de Vries
BRD | Director/Board Member | 67 | 2014-11-12 |
Simon Turton
BRD | Director/Board Member | 59 | 2014-12-11 |
Stephen Stamp
BRD | Director/Board Member | 65 | 2019-09-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.76% | -16.67% | - | - | 3.8M | |
| -3.10% | -4.19% | +32.67% | +59.47% | 65.28B | |
| +0.33% | +0.33% | +10.16% | +78.07% | 54.57B | |
| +0.16% | +1.73% | +9.89% | +102.10% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 45.03B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 42.17B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.42B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.71B | |
| +1.11% | +15.18% | +60.27% | +49.33% | 26.5B | |
| +4.39% | -5.87% | +26.50% | -7.92% | 24.01B | |
| Average | -1.07% | -0.17% | +45.84% | +154.67% | 42.59B | |
| Weighted average by Cap. | -0.29% | -0.59% | +42.59% | +153.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | - | - |
| Net Debt | - | - |
Employees
11
